Insys Therapeutics Inc (INSY)

HEALTH CARE: PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS

10220 SOUTH 51ST STREET PHOENIX, AZ 85044

NeoPharm is a biopharmaceutical company engaged in the research, development and commercialization of drugs for the treatment of cancer. Co. has built a drug portfolio based on its two proprietary technology platforms: the NeoLipid? liposomal drug delivery system, and a tumor-targeting toxin platform. As of Dec 31 2006, Co. had four drug product candidates in various stages of clinical development for the treatment of cancer. Co.'s core drug product candidate is CINTREDEKIN BESUDOTOX, a tumor-targeting toxin being developed as a treatment for glioblastoma multiforme, which is a form of brain cancer.
Insys Therapeutics, Inc., based in Phoenix, Arizona, is a biopharmaceutical company focused on discovering, developing and commercializing innovative products to address chemotherapy-induced nausea and vomiting (CINV), pain management and other central nervous system disorders. It seeks to apply new and proprietary formulations and delivery methods to existing pharmaceutical compounds in order to achieve enhanced efficacy, faster onset of action, reduced side effects, convenient delivery and increased patient compliance. Its drug development program is based on existing compounds with known safety, efficacy and commercialization histories.

Data based on most recent fiscal year report
Market Cap469.248 Million Shares Outstanding73.32 Million Avg Volume1.452 Million
1-Yr BETA vs S&P TR1.357 Current Ratio0.85 Quick Ratio0.77
View SEC Filings from INSY instead.
Q2 2018 All Institutions Hedge Funds 1
To trade INSY now:
Filers who had this stock in their top 10: 0 0 (0.0%)
13F Filers holding this stock: 101 8 (0.76%)
Aggregate 13F shares on 06/30/2018: 13.458 Million 3.903 Million
Aggregate 13F shares on 03/31/2018: 13.288 Million 3.881 Million
Percent change: 1.28% 0.57%
Funds creating new positions: 15 2
Funds Adding to an existing position: 31 2
Funds closing out their position: 21 5
Funds reducing their position: 20 3
1 hedge funds as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding INSY (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to

Exclude:

Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Acquired or Disposed Shares Owned Following Transaction Direct/Indirect Ownership

LONG ANDREW G - Officer CHIEF FINANCIAL OFFICER

2018-08-07 A 5,000 a 5,000 direct

BOHLEN ELIZABETH - Director

2018-08-07 A 6,000 a 6,000 direct

LONG ANDREW G - Officer CHIEF FINANCIAL OFFICER

2018-08-07 D 5,000 d 10,000 direct

BOHLEN ELIZABETH - Director

2018-08-07 A 24,000 a 24,000 direct
Click here to report any possible errors with this stock listing.

Elevate your investments